- cafead Feb 26, 2019 at 09:52: AM
via Months after securing a lightning fast approval for the use of the drug in frontline ovarian cancer — widening their lead over the cluster of other PARPs including Tesaro’s (now GSK’s) Zejula and Clovis’ Rubraca — Lynparza has shown promise in helping patients with BRCA-mutated metastatic pancreatic cancer live longer without their cancer progressing in a late-stage study.
article source
article source